Back to Peptide Index

AOD-9604

Weight LossEvidence Level: researchNot FDA-approved for clinical use; extensive ongoing research highlights its potential for treating obesity and metabolic disorders.
Peptide #11

AOD-9604 is a modified peptide engineered from the growth hormone fragment (amino acids 176-191) to specifically target adipose (fat) tissues. Its primary function is to promote lipolysis (fat breakdown) and inhibit lipogenesis (fat formation), offering significant advantages for weight loss and metabolic improvements.

Alternative Names:

Advanced Obesity Drug-9604

Overview

AOD-9604 is a synthetic peptide fragment derived from human growth hormone, designed to directly stimulate fat metabolism, enabling targeted fat loss without the systemic side effects associated with full-length HGH.

How It Works

AOD-9604 enhances lipolysis and inhibits lipogenesis, making it a promising candidate for obesity management and weight-loss therapies.

Clinical Effects

Promotes fat loss, improves metabolic function, preserves lean muscle mass during fat loss.

Therapeutic Applications

Obesity management, metabolic syndrome, joint health, and osteoarthritis.

Research Studies

Clinical Trials

Limited human studies exist, indicating initial safety but necessitating further extensive research for definitive long-term safety and efficacy conclusions.

Preclinical Studies

Animal studies show significant weight loss and improved body composition, reduced inflammation, and improved cartilage health.

Frequently Asked Questions

Is AOD-9604 legally available? Yes, for research purposes. Have human trials been conducted? Limited studies exist. What are known side effects? Minimal side effects in preclinical trials. How is it administered? Subcutaneous injections. Does it support muscle growth? Preserves lean muscle mass during fat loss. Is it compatible with other peptides or medications? Interactions are not well-studied.

Quick Information

Safety Information

Safety Profile

Minimal side effects compared to conventional therapies; more rigorous, controlled studies needed for comprehensive safety validation.

Contraindications

Side Effects: Preclinical trials suggest minimal side effects; however, comprehensive long-term safety profiles have yet to be firmly established. Safety Profile: Minimal side effects compared to conventional therapies; more rigorous, controlled studies needed for comprehensive safety validation.

Side Effects

Preclinical trials suggest minimal side effects; however, comprehensive long-term safety profiles have yet to be firmly established.

Research References

Heffernan, M.A., et al. (2001). AOD-9604 selectively induces lipolysis and inhibits lipogenesis in adipocytes. Journal of Endocrinological Investigation. Ng, F.M., et al. (2000). Human growth hormone fragment 176-191 enhances insulin sensitivity and promotes lipolysis. Hormone Research in Paediatrics. Wittert, G.A., et al. (2009). Safety assessment of AOD-9604: an anti-obesity peptide. International Journal of Obesity. Stier, H., et al. (2013). The effect of AOD-9604 on joint health and cartilage repair in animal models. Journal of Clinical Rheumatology.

Additional Resources

View Source